DLA
LLY icon

Douglas Lane & Associates’s Eli Lilly LLY Stock Holding History

Douglas Lane & Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43M Buy
2,861
+208
+8% +$213K 0.05% 138
2026
Q1 		$2.44M Buy
2,653
+2
+0.1% +$2.03K 0.04% 141
2025
Q4 		$2.85M Sell
2,651
-295
-10% -$282K 0.04% 139
2025
Q3 		$2.25M Sell
2,946
-39
-1% -$29K 0.03% 142
2025
Q2 		$2.33M Hold
2,985
– – 0.03% 139
2025
Q1 		$2.47M Buy
2,985
+162
+6% +$135K 0.04% 139
2024
Q4 		$2.18M Buy
2,823
+278
+11% +$230K 0.03% 141
2024
Q3 		$2.25M Sell
2,545
-77
-3% -$69.2K 0.03% 141
2024
Q2 		$2.37M Sell
2,622
-323
-11% -$258K 0.03% 139
2024
Q1 		$2.29M Sell
2,945
-322
-10% -$229K 0.03% 141
2023
Q4 		$1.9M Sell
3,267
-161
-5% -$94K 0.03% 141
2023
Q3 		$1.84M Buy
3,428
+19
+0.6% +$9.79K 0.03% 133
2023
Q2 		$1.6M Sell
3,409
-2
-0.1% -$839 0.03% 139
2023
Q1 		$1.17M Buy
3,411
+171
+5% +$57.7K 0.02% 152
2022
Q4 		$1.19M Buy
3,240
+5
+0.2% +$1.77K 0.02% 150
2022
Q3 		$1.05M Sell
3,235
-85
-3% -$26.9K 0.02% 149
2022
Q2 		$1.08M Sell
3,320
-124
-4% -$37.2K 0.02% 149
2022
Q1 		$986K Sell
3,444
-413
-11% -$106K 0.01% 154
2021
Q4 		$1.06M Buy
3,857
+15
+0.4% +$3.8K 0.01% 153
2021
Q3 		$888K Sell
3,842
-393
-9% -$97K 0.01% 153
2021
Q2 		$972K Buy
4,235
+8
+0.2% +$1.61K 0.01% 149
2021
Q1 		$790K Sell
4,227
-448
-10% -$87.6K 0.01% 149
2020
Q4 		$789K Sell
4,675
-69
-1% -$10.3K 0.01% 148
2020
Q3 		$702K Sell
4,744
-120
-2% -$18.6K 0.01% 145
2020
Q2 		$799K Buy
4,864
+407
+9% +$62.5K 0.02% 142
2020
Q1 		$618K Sell
4,457
-1,215
-21% -$167K 0.02% 148
2019
Q4 		$745K Buy
5,672
+200
+4% +$23.2K 0.01% 153
2019
Q3 		$612K Buy
5,472
+3
+0.1% +$334 0.01% 160
2019
Q2 		$606K Sell
5,469
-80
-1% -$9.42K 0.01% 165
2019
Q1 		$720K Sell
5,549
-150
-3% -$18.2K 0.01% 158
2018
Q4 		$659K Buy
5,699
+810
+17% +$90.5K 0.02% 158
2018
Q3 		$525K Sell
4,889
-1,871
-28% -$187K 0.01% 167
2018
Q2 		$577K Buy
+6,760
New +$555K 0.01% 160
2017
Q4 		– Sell
-2,375
Closed -$203K – 207
2017
Q3 		$203K Sell
2,375
-808
-25% -$66.3K ﹤0.01% 203
2017
Q2 		$262K Sell
3,183
-3,321
-51% -$271K 0.01% 185
2017
Q1 		$547K Sell
6,504
-759
-10% -$60.8K 0.01% 170
2016
Q4 		$534K Buy
7,263
+209
+3% +$15.6K 0.01% 173
2016
Q3 		$566K Sell
7,054
-425
-6% -$34K 0.02% 167
2016
Q2 		$589K Sell
7,479
-153
-2% -$11.5K 0.02% 168
2016
Q1 		$550K Buy
+7,632
New +$577K 0.02% 169

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
ONB
Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
GIM
Goelzer Investment Management Carmel, Indiana $2.29B AUM 39.12% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Douglas Lane & Associates's LLY Position: Q2 2026 in Review

Douglas Lane & Associates increased its Eli Lilly (LLY) stake by 7.8% in Q2 2026, buying an estimated $213K and bringing the position to 2,861 shares worth $3.43M. The position accounts for 0.05% of the portfolio, ranked #138.

Douglas Lane & Associates first reported a position in LLY in Q1 2016 and has held it in 40 quarters since. 1,816 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Douglas Lane & Associates held 2,861 shares of Eli Lilly worth $3.43M as of Q2 2026.
  • Douglas Lane & Associates bought 208 Eli Lilly shares in Q2 2026, an estimated $213K.
  • Eli Lilly made up 0.05% of Douglas Lane & Associates's portfolio in Q2 2026, its #138 holding.
  • Douglas Lane & Associates first reported a position in Eli Lilly in Q1 2016 and has held it in 40 quarters since.
  • 1,816 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Douglas Lane & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.